Education
About Us
Working with TipRanks
Follow Us
Xeris Pharmaceuticals (XERS)
NASDAQ:XERS
XERS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.69 - $6.07
Previous CloseN/A
Volume530.95K
Average Volume (3M)3.61M
Market Cap
$858.99M
Enterprise Value$626.20M
Total Cash (Recent Filing)-$32.27M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.39
Next Earnings
May 07, 2025EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding153,940,140
10 Day Avg. Volume4,228,978
30 Day Avg. Volume3,609,012
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.40
Price to Cash Flow (P/CF)113.20
P/FCF Ratio127.40
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.77
Enterprise Value/Ebitda-44.75
Forecast
1Y Price Target
$6.10Price Target Upside20.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceXeris' record 4Q24 performance marks a transformative inflection point with accelerating commercial momentum and first-time positive adjusted EBITDA, which is a strong positive setup going into 2025.
Market ValuationXERS stock is materially undervaluing the business at just 2.7x EV/REV, which is considered too cheap given its growth.
Revenue GrowthXeris reported 4Q24 financials with total net product revenues of $57.0M, representing ~34% Y/Y growth and marking the 13th consecutive quarter of >20% growth.
Bears Say
Partnership TerminationAmgen terminated their XeriJect license agreement with Xeris, which might weigh on the stock incrementally.
Stock Price ReactionDespite recent stock strength, the stock is still viewed as undervalued.
---
Ownership Overview
6.08% Insiders
8.09% Mutual Funds
9.75% Other Institutional Investors
66.32% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
XERS FAQ
What was Xeris Pharmaceuticals’s price range in the past 12 months?
Xeris Pharmaceuticals lowest stock price was $1.69 and its highest was $6.07 in the past 12 months.
What is Xeris Pharmaceuticals’s market cap?
Xeris Pharmaceuticals’s market cap is $858.99M.
When is Xeris Pharmaceuticals’s upcoming earnings report date?
Xeris Pharmaceuticals’s upcoming earnings report date is May 07, 2025 which is in 35 days.
How were Xeris Pharmaceuticals’s earnings last quarter?
Xeris Pharmaceuticals released its earnings results on Mar 06, 2025. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.056 by $0.026.
Is Xeris Pharmaceuticals overvalued?
According to Wall Street analysts Xeris Pharmaceuticals’s price is currently Undervalued.
Does Xeris Pharmaceuticals pay dividends?
Xeris Pharmaceuticals does not currently pay dividends.
What is Xeris Pharmaceuticals’s EPS estimate?
Xeris Pharmaceuticals’s EPS estimate is -0.05.
How many shares outstanding does Xeris Pharmaceuticals have?
Xeris Pharmaceuticals has 153,940,140 shares outstanding.
What happened to Xeris Pharmaceuticals’s price movement after its last earnings report?
Xeris Pharmaceuticals reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.056. Following the earnings report the stock price went up 9.549%.
Which hedge fund is a major shareholder of Xeris Pharmaceuticals?
Currently, no hedge funds are holding shares in XERS
---
Xeris Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.10 (20.08% Upside)
$6.10 (20.08% Upside)
Blogger Sentiment
Bullish
XERS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 598.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $217.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 16.6%
Last 30 Days ▲ 16.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
148.41%
12-Months-Change
Fundamentals
Return on Equity
222.83%
Trailing 12-Months
Asset Growth
-3.42%
Trailing 12-Months
Company Description
Xeris Pharmaceuticals
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
---
XERS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Xeris Biopharma's earnings call highlighted significant revenue growth and positive developments in their product portfolio, particularly with Recorlev and Gvoke. The company also achieved positive adjusted EBITDA for the first time. Despite the decline in Keveyis revenue and anticipated pressure on its reimbursement, the company is optimistic about its growth prospects for 2025.Read More>---
XERS Stock 12 Month Forecast
Average Price Target
$6.10
▲(20.08% Upside)
Technical Analysis
MannKind
―
EyePoint Pharmaceuticals
―
Rigel
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Best Analysts Covering XERS
1 Year
1 Year Success Rate
16/23 ratings generated profit
1 Year Average Return
+37.88%
reiterated a buy rating 23 days ago
Copying Roanna Ruiz's trades and holding each position for 1 Year would result in 69.57% of your transactions generating a profit, with an average return of +37.88% per trade.
---